NICE state in the appraisal that the most plausible incremental cost effectiveness ratio (ICER) for trastuzumab emtansine (without the patient access scheme) was above the ICER range that would normally be considered to be a cost effective use of NHS resources. and concluded that the size of the discount in the patient access scheme meant that it was still unable to recommend trastuzumab emtansine.
Trastuzumab emtansine remains available to NHS patients in England via the Cancer Drugs Fund.